Wild-harvest vs. cultivated supply: the long thaw

The default sourcing model for commercial botanicals through most of the twentieth century was wild-harvest: material collected from naturally occurring stands, typically by cooperative growers operating to a traditional harvest pattern. Over the last fifteen years, cultivated supply has gained share across most of the lead botanicals — driven by demand growth, chemotype consistency requirements, and the analytical specifications discussed elsewhere. The transition is uneven and far from complete, and it is not the right answer in every case. This note sets out the working pattern.

Where cultivated supply has won

Bacopa is the clearest case. Cultivation programmes in Kerala and Tamil Nadu now supply the majority of commercial Bacopa material to international ingredient buyers. The species is amenable to controlled cultivation, bacoside content is reasonably stable under cultivation conditions, and the analytical specification — bacoside content at the 20% band or higher — can be reliably hit through the cultivation-and-processing chain. Wild-harvested Bacopa persists in some regional traditional-medicine markets but is no longer the working source for international supply.

Moringa follows a similar pattern. The species is genuinely cultivated rather than collected at commercial scale; wild-harvest Moringa in the volumes that international supply requires is no longer a meaningful category. The cultivation model in India and parts of Africa supplies a reasonably elastic supply curve into the international market.

Where wild-harvest still has the working answer

Tongkat Ali sits at the other end. Cultivation programmes for Eurycoma longifolia operate on extended planting-to-harvest cycles — the root mass that carries the commercial chemotype takes years to develop — and the cultivated chemotype, when production has reached scale, sometimes presents a different quassinoid profile than the wild-harvested material that the market has historically specified against. The cultivation share is rising; the cultivated material is not yet a one-for-one substitute for wild-harvested material at premium specifications.

Noble Kava is structurally a wild-harvest-and-traditional-cultivation category. The noble varietals are grown within cooperative farming systems that are closer to the village level than to the agricultural plantation level; the chemotype consistency comes from the varietal selection and the agronomic discipline at the cooperative rather than from industrial cultivation. The Pacific kava model is neither pure wild-harvest nor industrial cultivation; it is a third model, and it works.

Kanna (Sceletium tortuosum) sits closer to the noble Kava pattern. Cooperative cultivation in the Western and Northern Cape, paired with chemotype-aware fermentation protocols, supplies the international market. Wild-harvest Sceletium is a smaller component, and the supply-side trajectory is toward cultivated material with documented cultivation and processing controls.

The chemotype question

The wild-harvest-to-cultivation transition raises a chemotype question that has not always been resolved cleanly. Wild-harvested material reflects the natural distribution of chemotype within the species in its native range — variability included. Cultivated material, by varietal selection, tends to converge on a narrower chemotype band. For some ingredients this is straightforwardly good: tight chemotype means consistent finished-product profile.

For others, the cultivated chemotype may differ from the chemotype the market has historically specified. The market specification, after all, was set against the wild material. When cultivation supplies a different profile under the same species name, the buyer has to choose: accept the cultivated chemotype as the new baseline, maintain a wild-harvest premium tier, or operate both. Most premium-tier buyers operate both for the ingredients where the divergence is material.

Chain of custody

Cultivated supply produces better chain-of-custody documentation almost by definition: the cultivation programme runs on lot-level records that propagate through to the commercial material. Wild-harvest chain-of-custody, where it is well-managed, runs on cooperative-level intake records, varietal verification at the cooperative gate, and chemotype documentation at the primary processing facility. Both can produce defensible documentation for regulatory and counterparty audit; the cultivated model produces it with less per-batch friction.

Where wild-harvest persists as the working model — Tongkat Ali, certain Pacific kava cooperatives, parts of the Sceletium supply — the chain-of-custody discipline has to do more of the work. Cooperative-level intake records, named cooperative gates, chemotype documentation per intake lot, and named partner laboratory verification are the working response. The model is operationally heavier than cultivated supply; the chemotype and category-protection benefits, where they apply, justify the operational weight.

The decade ahead

The cultivation share will continue to rise across most categories. The exceptions are the ingredients where the cultivated chemotype is not yet a one-for-one substitute for the wild material at premium specifications, where the cooperative-level model is the chemotype-protection mechanism, or where the traditional category framing carries commercial weight. These exceptions are real and not erodable within a single decade.

For ingredient buyers, the working question per ingredient is whether the cultivation transition has reached the point where cultivated material clears the buyer's specification. The answer differs by ingredient, by specification tier, and by claim framework. The working answer for each Motark-supplied ingredient is documented in the compound register.